VEGFA and nonpapillary renal cell carcinoma: Therefore, targeting angiogenesis was hypothesized to be especially important in ccRCC, and several clinical trials have shown that targeted therapies against the VEGF signaling axis (sunitinib, pazopanib, axitinib, cabozantinib, etc.), have provided significant clinical benefits for patients with ccRCC [5,6,7,8,9].